Detailed product reference
Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.
Product overview
Lixiana is a direct oral factor-Xa anticoagulant. Dose depends on indication, weight, renal function and other factors.
Read source section ↗Mechanism of action
Directly inhibits factor Xa and reduces thrombin generation; bleeding risk must be balanced against clot prevention.
Read source section ↗Japanese indications & eligibility
Japanese uses cover selected AF stroke prevention, VTE treatment/prevention, CTEPH and specified orthopedic procedures.
Read source section ↗Administration & dose differences
Common adult doses are 30 mg daily at ≤60 kg and 60 mg at >60 kg, with renal/drug adjustments; 15 mg has restricted elderly AF criteria.
Read source section ↗Adverse effects & key risks
Major risk is bleeding, including intracranial/GI bleeding. Do not stop treatment without a clinical plan.
Read source section ↗Contraindications & special populations
Contraindications include active significant bleeding and specified renal/hepatic conditions; renal thresholds differ by indication.
Read source section ↗Drug interactions
Review other antithrombotics, NSAIDs and P-gp inhibitors; procedures and switching require a plan.
Read source section ↗Assessment & monitoring
Monitor renal/hepatic function, hemoglobin and bleeding; routine INR is not a dose-titration measure for edoxaban.
Read source section ↗Storage & handling
Store at room temperature. The photo shows the Japanese 30 mg box.
Read source section ↗Sources & verification
Product checked ·
- PMDA electronic package insert ↗www.pmda.go.jp
Primary source for mechanism, indications, doses and risks; revision: 2025-11.
- Manufacturer information ↗www.medicalcommunity.jp
Official product or related information; professional portals may require identity confirmation.
- Wikipedia: ingredient background ↗en.wikipedia.org
Background reference; Japanese approvals and administration are governed by PMDA sources.
